These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17941964)

  • 21. Direct assessment of functional abilities: relevance to persons with schizophrenia.
    McKibbin CL; Brekke JS; Sires D; Jeste DV; Patterson TL
    Schizophr Res; 2004 Dec; 72(1):53-67. PubMed ID: 15531407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
    Silva de Lima M; de Jesus Mari J; Breier A; Maria Costa A; Pondé de Sena E; Hotopf M
    J Clin Psychiatry; 2005 Jul; 66(7):831-8. PubMed ID: 16013897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of therapeutic response in schizophrenia. A critical survey.
    Collins EJ; Hogan TP; Desai H
    Schizophr Res; 1991 Oct; 5(3):249-53. PubMed ID: 1684722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Atipical antipsychotics in relation with social functioning].
    Vrdoljak M; Sesar MA; Ivezić SS
    Med Arh; 2007; 61(4):244-7. PubMed ID: 18298001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The assessment of quality of life in clinical practice in patients with schizophrenia.
    Karow A; Wittmann L; Schöttle D; Schäfer I; Lambert M
    Dialogues Clin Neurosci; 2014 Jun; 16(2):185-95. PubMed ID: 25152657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schizophrenia and Bipolar Affective Disorder: a Dimensional Approach.
    Aykut DS; Arslan FC; Özkorumak E; Tiryaki A
    Psychiatr Danub; 2017 Jun; 29(2):141-147. PubMed ID: 28636571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
    Motlová L; Spaniel F; Höschl C; Balon R
    Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying improvable employment-related factors in schizophrenia patients.
    Hasegawa T; Hashimoto T; Kanahara N; Yamanaka H; Ishige M; Sato Y; Iyo M
    Psychiatry Res; 2018 Aug; 266():199-205. PubMed ID: 29870957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.
    Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A
    BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
    Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
    Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients.
    Vernon MK; Revicki DA; Awad AG; Dirani R; Panish J; Canuso CM; Grinspan A; Mannix S; Kalali AH
    Schizophr Res; 2010 May; 118(1-3):271-8. PubMed ID: 20172695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study.
    Guo X; Zhang Z; Zhai J; Fang M; Hu M; Wu R; Liu Z; Zhao J;
    Compr Psychiatry; 2012 Oct; 53(7):1006-12. PubMed ID: 22516246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.
    Swartz MS; Perkins DO; Stroup TS; McEvoy JP; Nieri JM; Haak DC
    Schizophr Bull; 2003; 29(1):33-43. PubMed ID: 12908659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deficits in neurocognition, theory of mind, and social functioning in patients with schizophrenic disorders: are they related?
    Bâ MB; Zanello A; Varnier M; Koellner V; Merlo MC
    J Nerv Ment Dis; 2008 Feb; 196(2):153-6. PubMed ID: 18277224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.